FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Nash Duane
  2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [IMUX] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Executive Chairman
(Last)
(First)
(Middle)
1200 AVENUE OF THE AMERICAS, SUITE 200		 3. Date of Earliest Transaction (Month/Day/Year)
03/04/2024
(Street)

NEW YORK, NY 10036		 4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $ 13.63 03/04/2024   D     9,986   (1) 07/22/2029 Common Stock 9,986 (1) 0 D  
Stock Option $ 13.63 03/04/2024   D     19,973   (1) 07/22/2029 Common Stock 19,973 (1) 0 D  
Stock Option $ 12.3 03/04/2024   D     15,000   (1) 07/02/2030 Common Stock 15,000 (1) 0 D  
Stock Option $ 12.3 03/04/2024   D     30,000   (1) 07/02/2030 Common Stock 30,000 (1) 0 D  
Stock Option $ 17 03/04/2024   D     120,000   (1) 10/22/2030 Common Stock 120,000 (1) 0 D  
Stock Option $ 15.44 03/04/2024   D     90,000   (1) 04/15/2031 Common Stock 90,000 (1) 0 D  
Stock Option $ 14.77 03/04/2024   D     10,000   (1) 06/10/2031 Common Stock 10,000 (1) 0 D  
Stock Option $ 10.88 03/04/2024   D     75,000   (1) 03/10/2032 Common Stock 75,000 (1) 0 D  
Stock Option $ 3.4 03/04/2024   D     10,000   (1) 06/15/2032 Common Stock 10,000 (1) 0 D  
Stock Option $ 1.72 03/04/2024   A   379,959     (1)   (1) Common Stock 379,959 (1) 379,959 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Nash Duane
1200 AVENUE OF THE AMERICAS, SUITE 200
NEW YORK, NY 10036		   X     Executive Chairman  

Signatures

 /s/ Duane Nash   03/06/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.